Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small-molecule APIs to advance biocatalysis across pharma.
Codexis leverages directed evolution and computational biology to develop powerful, sustainable biocatalysts for manufacturing small-molecule APIs, a technology critical to partners worldwide and used in drugs like Paxlovid. Mandy Vink, VP of Business Development at Codexis, explores market trends, Codexis’ position in the industry and its collaborations, and what currently drives adoption among innovators and CDMOs.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
